A phase II, observer-blind, randomized, parallel groups, multicenter, exploratory clinical study to evaluate the immunogenicity and safety of one and two 0.25 mL intramuscular doses of a commercially available influenza vaccine versus two 0.25mL intramuscular doses of a commercially available influenza vaccine in healthy children.

Trial Profile

A phase II, observer-blind, randomized, parallel groups, multicenter, exploratory clinical study to evaluate the immunogenicity and safety of one and two 0.25 mL intramuscular doses of a commercially available influenza vaccine versus two 0.25mL intramuscular doses of a commercially available influenza vaccine in healthy children.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2014

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 23 Jan 2012 Actual initiation date is Nov 2007 and actual patient number is 89 as reported by ClinicalTrials.gov (Extension trial: NCT00644540).
    • 23 Jan 2012 Actual initiation date is Nov 2007 and actual patient number is 89 as reported by ClinicalTrials.gov (Extension trial: NCT00644540).
    • 23 Jan 2012 Actual end date is Jun 2008 as reported by ClinicalTrials.gov (Extension trial: NCT00644540).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top